Improving outcomes for care partners of individuals with traumatic brain injury: Results for a mHealth randomized control trial of the CareQOL app.

Objective: To test the efficacy of a randomized control trial low-touch mobile health intervention designed to promote care partner self-awareness and self-care.

Design: This randomized controlled trial (RCT) included a baseline assessment of self-report surveys of health-related quality of life (HRQOL), care partner-specific outcomes, and the functional/mental status of the person with TBI, as well as a 6-month home monitoring period that included three daily questions about HRQOL, monthly assessments of 12 HRQOL domains, and the use of a Fitbit® to continuously monitor physical activity and sleep. HRQOL surveys were repeated at 3- and 6-months post-home monitoring.

Clinically meaningful classes of financial toxicity for patients with diabetes.

Aims: This study aims to improve the interpretability and clinical utility of the COmprehensive Score for financial Toxicity-Functional Assessment of Chronic Illness Therapy (COST-FACIT) by identifying distinct financial toxicity classes in adults with diabetes.

Methods: Data included a sample of 600 adults with Type 1 or Type 2 diabetes and high A1c. Latent Class Analysis was used to identify subgroups of patients based on COST-FACIT score patterns.

Long-term adverse event risks of oral JAK inhibitors versus immunomodulators: a literature review.

The long-term adverse event risks associated with oral Janus kinase (JAK) inhibitors compared to broader immunomodulators are poorly understood, with limited comparative studies available. This study aims to assess the long-term adverse event risks of oral JAK inhibitors compared to broader immunomodulators in dermatology. A PubMed search included terms such as specific drug names and "adverse events," "long-term safety," "malignancy," "cardiovascular events," and/or "infections.